Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,039 shares of the company’s stock after acquiring an additional 6,232 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Olema Pharmaceuticals were worth $537,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vontobel Holding Ltd. purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $62,000. SG Americas Securities LLC boosted its stake in shares of Olema Pharmaceuticals by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock valued at $102,000 after buying an additional 4,419 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $111,000. Conway Capital Management Inc. purchased a new stake in shares of Olema Pharmaceuticals in the third quarter valued at approximately $119,000. Finally, Portland Investment Counsel Inc. purchased a new stake in shares of Olema Pharmaceuticals in the third quarter valued at approximately $143,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider David C. Myles sold 12,452 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.38, for a total value of $116,799.76. Following the completion of the transaction, the insider now directly owns 611,947 shares of the company’s stock, valued at $5,740,062.86. The trade was a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was bought at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the acquisition, the insider now owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. The trade was a 4.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 773,797 shares of company stock worth $5,414,609. 19.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 5th.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $4.61 on Monday. Olema Pharmaceuticals, Inc. has a 1-year low of $4.07 and a 1-year high of $16.62. The company has a market cap of $264.14 million, a PE ratio of -2.11 and a beta of 2.11. The stock’s 50 day moving average price is $5.35 and its 200 day moving average price is $8.82.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.